Incannex Healthcare (IXHL) Projected to Release Quarterly Earnings on Friday

Incannex Healthcare (NASDAQ:IXHL) is projected to release its Q1 2027 results on Friday, November 13th. Analysts expect Incannex Healthcare to announce earnings of ($0.66) per share and revenue of $10.00 million for the quarter. Parties may visit the company’s upcoming Q1 2027 earnings results page for the latest details on the call scheduled for Friday, November 20, 2026 at 9:30 AM ET.

Incannex Healthcare (NASDAQ:IXHL) last released its quarterly earnings results on Saturday, September 26th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.27). On average, analysts expect Incannex Healthcare to post ($2.63) EPS for the current fiscal year and ($2.77) EPS for the next fiscal year.

Incannex Healthcare Stock Performance

Shares of NASDAQ IXHL opened at $2.01 on Wednesday. The firm has a market cap of $25.23 million, a PE ratio of -1.19 and a beta of 7.00. The firm has a fifty day moving average of $3.00 and a 200 day moving average of $3.96. Incannex Healthcare has a one year low of $1.96 and a one year high of $14.91.

Analyst Ratings Changes

Several research firms have issued reports on IXHL. Zacks Research downgraded shares of Incannex Healthcare from a “hold” rating to a “strong sell” rating in a report on Tuesday, October 6th. Wall Street Zen lowered shares of Incannex Healthcare from a “hold” rating to a “sell” rating in a research report on Saturday, October 3rd. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Incannex Healthcare in a research note on Thursday, October 15th. One investment analyst has rated the stock with a Buy rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Reduce” and a consensus price target of $18.00.

Incannex Healthcare Company Profile

Incannex Healthcare Limited (NASDAQ: IXHL) is an Australia-based clinical-stage pharmaceutical company developing cannabinoid- and psychedelic-assisted therapies for conditions with significant unmet medical needs. The company’s research programs are focused on areas including sleep disorders, pain, inflammation, mental health and traumatic brain injury. Incannex’s lead programs have included IHL-42X, an investigational combination therapy being developed for obstructive sleep apnea, and IHL-675A, a cannabinoid-based therapy studied for inflammatory conditions.